TL-925

DRUG6 trials

Sponsors

Telios Pharma, Inc.

Conditions

Allergic ConjunctivitisDry Eye Disease

Phase 2

A Study of TL-925 as a Treatment for Dry Eye Disease

CompletedNCT05745064

Telios Pharma, Inc.Dry Eye Disease

Start: 2023-02-27End: 2023-07-11Updated: 2023-11-18

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Telios Pharma, Inc.Allergic Conjunctivitis

Start: 2023-11-30End: 2024-01-31Target: 70Updated: 2023-12-01

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Active, not recruitingNCT06225973

Telios Pharma, Inc.Dry Eye Disease

Start: 2024-02-06End: 2024-12-31Target: 880Updated: 2024-07-10

A Study Of TL-925 For The Treatment of AC

CompletedNCT06293820

Telios Pharma, Inc.Allergic Conjunctivitis

Start: 2024-04-11End: 2024-05-21Updated: 2024-07-03

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

RecruitingNCT06686472

Telios Pharma, Inc.Allergic Conjunctivitis

Start: 2024-10-03End: 2024-12-10Target: 66Updated: 2024-11-13

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

RecruitingNCT07220408

Telios Pharma, Inc.Allergic Conjunctivitis

Start: 2025-10-23End: 2026-02-28Target: 60Updated: 2025-11-25